Join the 'Namzaric' group to help and get support from people like you.
Posted 3 Aug 2015 by Drugs.com
MONDAY, Aug. 3, 2015 – A class of drugs widely used to treat dementia – called cholinesterase inhibitors – could cause harmful weight loss in some patients, a new study suggests. These medications include Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine). "Our study provides evidence in a large, real-world population that cholinesterase inhibitors may contribute to clinically significant weight loss in a substantial proportion of older adults with dementia," study lead author Dr. Meera Sheffrin, a geriatrics fellow in the School of Medicine, at the University of California, San Francisco, said in a university news release. One expert said the findings point out a common problem for Alzheimer's patients. "Weight loss is a concern, not only for patients but also for their overwhelmed caregivers, who keep struggling with multiple challenges, including providing their ... Read more
Related support groups: Weight Loss, Dementia, Alzheimer's Disease, Aricept, Donepezil, Exelon, Mild Cognitive Impairment, Rivastigmine, Arteriosclerotic Dementia, Galantamine, Reminyl, Cachexia, Razadyne, Cognex, Namzaric, Razadyne ER, Tacrine, Arteriosclerotic Dementia w/ Depressive Features, Aricept ODT, Lewy Body Dementia